


The introduction of tyrosine kinase inhibitors has considerably improved the life expectancy for chronic myeloid leukemia (CML) patients. Evaluating health-related quality of life within the treatment pathway remains crucial. Using the Swedish CML register, we included 991 chronic phase chronic myeloid leukemia (CP-CML) adult patients diagnosed 2007 to 2017, with follow-up until 2018. We developed a multistate model to estimate the loss in life expectancy and loss in quality-adjusted life expectancy for the CP-CML patients compared to the general population.



(QALE) for female CP-CML patients aged 65 years.

Conclusions Despite a low loss in life expectancy, our study shows a considerable gap (loss) in quality-adjusted life expectancy for CP-CML patients compared with the general population. Further improvements in management of CP-CML are thus warranted to successfully address the prevailing medical needs.

Enoch Yi-Tung Chen

Email: enoch.yitung.chen@ki.se

Mind the Gap: Loss in Overall and Quality-adjusted Life Expectancy for Patients with Chronic Phase Chronic Myeloid Leukemia. Data from the Swedish CML Register Chen EYT, Dahlén T, Stenke L, Björkholm M, Hao S, Dickman PW, Clements MS Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden





Figure. Loss in life expectancy (LLE) and loss in quality-adjusted life expectancy (LQALE) with 95% CIs for female CP-CML patients in Sweden diagnosed during 2007 to 2017 over ages 45 to 85 years.

Loss in LE or QALE

Females





Department of Medical Epidemiology and Biostatistics, Karolinska Institutet